OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
This article was originally published in The Tan Sheet
Executive Summary
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices